Synergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis
- 1 August 2012
- journal article
- research article
- Published by Elsevier in Cancer Cell
- Vol. 22 (2) , 167-179
Abstract
No abstract availableKeywords
Funding Information
- European Research Council (ERC-AG-LS6)
- Deutsche Forschungsgemeinschaft
- National Institutes of Health (P01 CA92625, R37 AI054636)
- Leukemia and Lymphoma Society
This publication has 39 references indexed in Scilit:
- Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomicsNature, 2012
- Circular binary segmentation for the analysis of array-based DNA copy number dataBiostatistics, 2004
- P38SAPK2 phosphorylates cyclin D3 at Thr-283 and targets it for proteasomal degradationOncogene, 2004
- Overall Survival in Aggressive B-Cell Lymphomas Is Dependent on the Accumulation of Alterations in p53, p16, and p27The American Journal of Pathology, 2001
- Burkitt Lymphoma in the MouseJournal of Experimental Medicine, 2000
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- Cellular Origin of Human B-Cell LymphomasNew England Journal of Medicine, 1999
- The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors.1992
- RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangementCell, 1992
- Myc oncogene activation in B and T lymphoid tumoursProceedings of the Royal Society of London. B. Biological Sciences, 1985